Evidence map›Paper›PMID 42157851›Full record

ArticleACS medicinal chemistry letters2026

Lead Optimization of Xanthone Derivatives as Hepatitis B Virus cccDNA Reducers: Design, Synthesis, and Bioevaluation.

Lijun Guo, Xiaodong Chen, Xuejun Liu, Nian Liu, Kai Sun, Huiyi Hong, Dongmei Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lijun GuoKey Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.ORCID https://orcid.org/0000-0002-2235-8420
Xiaodong ChenShanghai Neutan Pharmaceutical Co., Ltd., Shanghai 201315, China.
Xuejun LiuShanghai Neutan Pharmaceutical Co., Ltd., Shanghai 201315, China.
Nian LiuKey Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
Kai SunShanghai Neutan Pharmaceutical Co., Ltd., Shanghai 201315, China.
Huiyi HongShanghai Neutan Pharmaceutical Co., Ltd., Shanghai 201315, China.
Dongmei ZhaoKey Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.ORCID https://orcid.org/0000-0001-5156-6125

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic hepatitis B virus (HBV) infection remains a significant global health challenge, yet current available treatment options are still limited. Roche first reported the efficacy of a class of xanthone derivatives in diminishing covalently closed circular DNA (cccDNA) levels; however, their coplanarity constrained their drug-likeness. We introduced more flexible and hydrophilic side chains to xanthones, yielding a series of compounds with enhanced antiviral activity and better pharmacokinetic (PK) profiles. The representative compound

Indexed as

Chronic hepatitis B (CHB)Covalently closed circular DNA (cccDNA) reducersHepatitis B virus (HBV)Xanthone derivatives

Identifiers

PMID42157851
PMCPMC13181487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.